Zinger Brief
- Dr. Dartiu da Silveira is a renowned Brazilian psychiatrist and a pioneer in psychedelics scientific research.
- Dr. Silveira will collaborate with Bienstar as a scientific advisor.
- The advisor will focus on ibogaine assisted therapies protocols, medical education programs and clinical research development.
What Happened
Bienstar Wellness has hired Dr. Dartiu Xavier da Silveira as a scientific consultant.
One of the most renowned Brazilian psychiatrists and a pioneer in scientific research on psychedelics in Brazil, the doctor and scientist will advise the development of clinical research projects and protocols for psychedelic-assisted therapies. He will also be collaborating with the psychiatric care team and the company’s medical education programs.
Why It Matters
Silveira is a professor at the Faculty of Medicine of the Federal University of São Paulo (Unifesp), a member of the American Psychiatric Association and the International Association of Analytical Psychology. In his 40 years of experience, he has developed an extensive clinical and academic career focused on the treatment of addictions and substance abuse. Likewise, he was one of the first researchers to study the therapeutic effects of psychedelic substances in Brazil.
“Prof. Dartiu da Silveira is, without a doubt, the medical professional with the most experience in the use of psychedelics among psychiatrists in Latin America. Having his knowledge and his human presence in our clinics will be a privilege for Bienstar,” says Bienstar Wellness CEO Marco Algorta.
Of note in the psychiatrist’s scientific activity is his participation in clinical trials with MDMA and observational studies with ibogaine, as well as his collaboration with Charles Grob (University of California) in the development of ayahuasca safety studies in the early 2000s. He is currently responsible for directing two studies focused on the clinical use of psilocybin (Unifesp).
What Is Bienstar Wellness?
Bienstar Wellness Corp. is a company focused on bringing alternative mental health treatments to Latin America.
The company will provide psychedelic-assisted psychotherapy with approved substances, through a network of clinics across the region, including Brazil, Mexico, Perú, Uruguay and Panama where it will start treating patients with depression, mood disorders and substance abuse, affecting over 16.3 million people in Brazil.
Last year, Novamind Inc. NVMDF — now owned by Numinus NUMIF — announced a strategic investment and advisory agreement with Bienstar Wellness to assist in the expansion of Latin America’s first network of integrative mental health clinics treating patients with psychedelic therapies.
Photo: Cottonbro, Pexels. Edited by Plastiboy.
Image and article originally from www.benzinga.com. Read the original article here.